Sclareol inhibits cell proliferation and sensitizes cells to the antiproliferative effect of bortezomib via upregulating the tumor suppressor caveolin-1 in cervical cancer cells

Zhang,Ting; Wang,Ting; Cai,Peiling

doi:10.3892/mmr.2017.6480

Sclareol inhibits cell proliferation and sensitizes cells to the antiproliferative effect of bortezomib via upregulating the tumor suppressor caveolin-1 in cervical cancer cells

Authors:
- Ting Zhang
- Ting Wang
- Peiling Cai
View Affiliations

Affiliations: Department of Medical Cell Biology and Genetics, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China, Department of Anatomy and Histology, School of Medicine, Chengdu University, Chengdu, Sichuan 610106, P.R. China
Published online on: April 13, 2017 https://doi.org/10.3892/mmr.2017.6480
Pages: 3566-3574
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The anticancer effect of sclareol has long been reported, however, the exact mechanisms underlying the antitumorigenic effect of sclareol in cervical carcinoma remain to be fully elucidated. The present study analyzed cell proliferation and cell apoptosis by MTT and FITC‑Annexin V assays. The protein levels of caveolin‑1 (Cav‑1) and copper-zinc superoxide dismutase (SOD)1 were determined by western blotting, and the interaction of Cav1 and HSC70 was investigated by co‑immunoprecipitation experiments. The present study found that sclareol inhibited cell proliferation and induced apoptosis in HeLa cells. Two cancer‑associated proteins, Cav1 and SOD1 were identified as potential targets of sclareol in HeLa cells. The expression of Cav1 increased when the cells were treated with sclareol, and the protein level of SOD1 was negatively correlated with Cav1. The overexpression of Cav1 enhanced the sensitivity of the HeLa cells to sclareol treatment and downregulated the protein level of SOD1, which exhibited potential associations between Cav1 and SOD1. In addition, sclareol significantly sensitized several cancer cells to the anticancer effect of bortezomib by targeting Cav1 and SOD1. Taken together, the results of the present study demonstrated that sclareol inhibited tumor cell growth through the upregulation of Cav1, and provides a potential therapeutic target for human cancer.

View Figures

View References

1	Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010. View Article : Google Scholar : PubMed/NCBI
2	Noori S, Hassan ZM and Salehian O: Sclareol reduces CD4+CD25+FoxP3+Treg cells in a breast cancer model in vivo. Iran J Immunol. 10:10–21. 2013.PubMed/NCBI
3	Noori S, Hassan ZM, Mohammadi M, Habibi Z, Sohrabi N and Bayanolhagh S: Sclareol modulates the Treg intra-tumoral infiltrated cell and inhibits tumor growth in vivo. Cellular Immunol. 263:148–153. 2010. View Article : Google Scholar
4	Wang L, He HS, Yu HL, Zeng Y, Han H, He N, Liu ZG, Wang ZY, Xu SJ and Xiong M: Sclareol, a plant diterpene, exhibits potent antiproliferative effects via the induction of apoptosis and mitochondrial membrane potential loss in osteosarcoma cancer cells. Mol Med Rep. 11:4273–4278. 2015.PubMed/NCBI
5	Sashidhara KV, Rosaiah JN, Kumar A, Bid HK, Konwar R and Chattopadhyay N: Cell growth inhibitory action of an unusual labdane diterpene, 13-epi-sclareol in breast and uterine cancers in vitro. Phytotherapy Res. 21:1105–1108. 2007. View Article : Google Scholar
6	Dimas K, Hatziantoniou S, Tseleni S, Khan H, Georgopoulos A, Alevizopoulos K, Wyche JH, Pantazis P and Demetzos C: Sclareol induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in immunodeficient mice. Apoptosis. 12:685–694. 2007. View Article : Google Scholar : PubMed/NCBI
7	Simmons GE, Taylor HE and Hildreth JEK: Caveolin-1 suppresses human immunodeficiency virus-1 replication by inhibiting acetylation of NF-κB. Virology. 432:110–119. 2012. View Article : Google Scholar : PubMed/NCBI
8	Garrean S, Gao XP, Brovkovych V, Shimizu J, Zhao YY, Vogel SM and Malik AB: Caveolin-1 regulates NF-kappaB activation and lung inflammatory response to sepsis induced by lipopolysaccharide. J Immunol. 177:4853–4860. 2006. View Article : Google Scholar : PubMed/NCBI
9	Wang XM, Kim HP, Song R and Choi AM: Caveolin-1 confers antiinflammatory effects in murine macrophages via the MKK3/p38 MAPK pathway. Am J Respir Cell Mol Biol. 34:434–442. 2006. View Article : Google Scholar : PubMed/NCBI
10	Huertas-Martinez J, Rello-Varona S, Herrero-Martin D, Barrau I, García-Monclús S, Sáinz-Jaspeado M, Lagares-Tena L, Núñez-Álvarez Y, Mateo-Lozano S, Mora J, et al: Caveolin-1 is down-regulated in alveolar rhabdomyosarcomas and negatively regulates tumor growth. Oncotarget. 5:9744–9755. 2014. View Article : Google Scholar : PubMed/NCBI
11	Bender FC, Reymond MA, Bron C and Quest AF: Caveolin-1 levels are down-regulated in human colon tumors and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 60:5870–5878. 2000.PubMed/NCBI
12	Belanger MM, Roussel E and Couet J: Caveolin-1 is down-regulated in human lung carcinoma and acts as a candidate tumor suppressor gene. Chest. 125 Supply 5:S1062004. View Article : Google Scholar
13	Fischer LR, Igoudjil A, Magrané J, Li Y, Hansen JM, Manfredi G and Glass JD: SOD1 targeted to the mitochondrial intermembrane space prevents motor neuropathy in the Sod1 knockout mouse. Brain. 134(Pt 1): 196–209. 2011. View Article : Google Scholar : PubMed/NCBI
14	Igoudjil A, Magrané J, Fischer LR, Kim HJ, Hervias I, Dumont M, Cortez C, Glass JD, Starkov AA and Manfredi G: In vivo pathogenic role of mutant SOD1 localized in the mitochondrial intermembrane space. J Neurosci. 31:15826–15837. 2011. View Article : Google Scholar : PubMed/NCBI
15	Somwar R, Erdjument-Bromage H, Larsson E, Shum D, Lockwood WW, Yang G, Sander C, Ouerfelli O, Tempst PJ, Djaballah H and Varmus HE: Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines. Proc Natl Acad Sci USA. 108:pp. 16375–16380. 2011; View Article : Google Scholar : PubMed/NCBI
16	Glasauer A, Sena LA, Diebold LP, Mazar AP and Chandel NS: Targeting SOD1 reduces experimental non-small-cell lung cancer. J Clin Invest. 124:117–128. 2014. View Article : Google Scholar : PubMed/NCBI
17	Kirchner P, Bug M and Meyer H: Ubiquitination of the N-terminal region of caveolin-1 regulates endosomal sorting by the VCP/p97 AAA-ATPase. J Biol Chem. 288:7363–7372. 2013. View Article : Google Scholar : PubMed/NCBI
18	Hayer A, Stoeber M, Ritz D, Engel S, Meyer HH and Helenius A: Caveolin-1 is ubiquitinated and targeted to intralumenal vesicles in endolysosomes for degradation. J Cell Biol. 191:615–629. 2010. View Article : Google Scholar : PubMed/NCBI
19	Chen SF, Wu CH, Lee YM, Tam K, Tsai YC, Liou JY and Shyue SK: Caveolin-1 interacts with Derlin-1 and promotes ubiquitination and degradation of cyclooxygenase-2 via collaboration with p97 complex. J Biol Chem. 288:33462–33469. 2013. View Article : Google Scholar : PubMed/NCBI
20	Chen SF, Liou JY, Huang TY, Lin YS, Yeh AL, Tam K, Tsai TH, Wu KK and Shyue SK: Caveolin-1 facilitates cyclooxygenase-2 protein degradation. J Cell Biochem. 109:356–362. 2010.PubMed/NCBI
21	Feldman R and Martinez JD: Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of EGFR. Biochim Biophys Acta. 1793:1387–1394. 2009. View Article : Google Scholar : PubMed/NCBI
22	Qi L, Zhang XD, Wu JC, Lin F, Wang J, DiFiglia M and Qin ZH: The role of chaperone-mediated autophagy in huntingtin degradation. PloS One. 7:e468342012. View Article : Google Scholar : PubMed/NCBI
23	Cuervo AM, Dice JF and Knecht E: A population of rat liver lysosomes responsible for the selective uptake and degradation of cytosolic proteins. J Biol Chem. 272:5606–5615. 1997. View Article : Google Scholar : PubMed/NCBI
24	Liang X, Wei SQ, Lee S, Fung JK, Zhang M, Tanaka A, Choi AM and Jin Y: p62 sequestosome 1/light chain 3b complex confers cytoprotection on lung epithelial cells after hyperoxia. Am J Respir Cell Mol Biol. 48:489–496. 2013. View Article : Google Scholar : PubMed/NCBI
25	Gómez-Sánchez R, Yakhine-Diop SM, Rodríguez-Arribas M, Bravo-San Pedro JM, Martínez-Chacón G, Uribe-Carretero E, de Castro DC Pinheiro, Pizarro-Estrella E, Fuentes JM and González-Polo RA: mRNA and protein dataset of autophagy markers (LC3 and p62) in several cell lines. Data Brief. 7:641–647. 2016. View Article : Google Scholar : PubMed/NCBI
26	Trimmer C, Bonuccelli G, Katiyar S, Sotgia F, Pestell RG, Lisanti MP and Capozza F: Cav1 suppresses tumor growth and metastasis in a murine model of cutaneous SCC through modulation of MAPK/AP-1 activation. Am J Pathol. 182:992–1004. 2013. View Article : Google Scholar : PubMed/NCBI
27	Aarhus M, Bruland O, Saetran HA, Mork SJ, Lund-Johansen M and Knappskog PM: Global gene expression profiling and tissue microarray reveal novel candidate genes and down-regulation of the tumor suppressor gene CAV1 in sporadic vestibular schwannomas. Neurosurgery. 67:998–1019. 2010. View Article : Google Scholar : PubMed/NCBI
28	Shi Y, Tan SH, Ng S, Zhou J, Yang ND, Koo GB, McMahon KA, Parton RG, Hill MM, Del Pozo MA, et al: Critical role of CAV1/caveolin-1 in cell stress responses in human breast cancer cells via modulation of lysosomal function and autophagy. Autophagy. 11:769–784. 2015. View Article : Google Scholar : PubMed/NCBI
29	Podar K, Shringarpure R, Tai YT, Simoncini M, Sattler M, Ishitsuka K, Richardson PG, Hideshima T, Chauhan D and Anderson KC: Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 64:7500–7506. 2004. View Article : Google Scholar : PubMed/NCBI
30	Mao M, Sudhahar V and Fukai T: P54: Nitroglycerin-induced loss of caveolin-1 results in eNOS dysfunction, peroxynitrite production and nitrate tolerance. Nitric Oxide 31, Supplement. 1:S362013. View Article : Google Scholar
31	Salem K, McCormick ML, Wendlandt E, Zhan F and Goel A: Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma. Redox Biol. 4:23–33. 2015. View Article : Google Scholar : PubMed/NCBI
32	Chen D, Frezza M, Schmitt S, Kanwar J and Dou QP: Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr Cancer Drug Targets. 11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
33	Kao C, Chao A, Tsai CL, Chuang WC, Huang WP, Chen GC, Lin CY, Wang TH, Wang HS and Lai CH: Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation. Cell Death Dis. 5:e15102014. View Article : Google Scholar : PubMed/NCBI
34	Kretowski R, Stypulkowska A and Cechowska-Pasko M: Efficient apoptosis and necrosis induction by proteasome inhibitor: Bortezomib in the DLD-1 human colon cancer cell line. Mol Cell Biochem. 398:165–173. 2015. View Article : Google Scholar : PubMed/NCBI
35	Miyamoto Y, Nakagawa S, Wada-Hiraike O, Seiki T, Tanikawa M, Hiraike H, Sone K, Nagasaka K, Oda K, Kawana K, et al: Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines. Oncol Rep. 29:51–57. 2013.PubMed/NCBI
36	Ando M, Hoyos V, Yagyu S, Tao W, Ramos CA, Dotti G, Brenner MK and Bouchier-Hayes L: Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther. 21:472–482. 2014. View Article : Google Scholar : PubMed/NCBI